顺铂和吉西他滨一线治疗转移性三阴性乳腺癌
IntJCancer.;(1):-11.
Cisplatinandgemcitabineasthefirstlinetherapyinmetastatictriplenegativebreastcancer.
ZhangJ,WangZ,HuX,WangB,WangL,YangW,LiuY,LiuG,DiG,HuZ,WuJ,ShaoZ.
DepartmentofMedicalOncology,FudanUniversityShanghaiCancerCenter,XuhuiDistrict,Shanghai,China;DepartmentofOncology,ShanghaiMedicalCollege,FudanUniversity,Shanghai,China.
Nostandardfirst-linetreatmentexistsforpatientswithmetastatictriple-negativebreastcancer(mTNBC).Inthissingle-arm,phaseIIstudy(NCT),weevaluatedtheefficacyandtolerabilityofcisplatinandgemcitabine(GP)asthefirst-linetherapyinmTNBC.EligiblewomenwerethosewhohadmeasurablediseasewithnopriorchemotherapyformTNBC.Allpatientsreceived21-day-cycleofcisplatin25mg/m(2)ondays1-3andgemcitabine1,mg/m(2)ondays1and8.Treatmentwascontinueduntildiseaseprogression,unacceptabletoxicityorupto8cycles.BRCA1/2mutationstatusandimmunohistochemicalbasalmarkerswereincludedinthecorrelativestudies.Sixty-fourpatientswiththemedianageof49yearswereenrolled.Thirtypatients(46.9%)had≤1yearfromdiagnosistorecurrence.Themedianprogressionfreesurvival(PFS)was7.2months(95%CI,5.6-8.9months)andoverallsurvival(OS)was19.1months(95%CI,12.4-25.8months)withmedianfollow-up42months.Patientsreceivedtreatmentforamedianofsixcycles.Theoverallresponseratewas62.5%.Themost娌荤枟鐧界櫆椋庢渶濂界殑涓撶鍖婚櫌鍖椾含鐧界櫆椋庢不鐤楃殑鏈�濂藉尰闄?
